Prostate Cancer | Norton Healthcare

Indication: Prostate Cancer

A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-resistant Prostate Cancer and DNA-Repair Anomalies

Metastatic Castration-resistant

Sub-indication: GU 16-37 Metastatic Castration-resistant prostate cancer

Line of Therapy: 1 previous line of taxane based chemo. 1 previous AR targeted therapy. No prior platinum therapy.

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Janssen Research & Development

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.